Disclosure Statement

It is the policy of The France Foundation to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All faculty and activity planners involved in the development of this activity have disclosed any significant financial interest or other relationship with manufacturer(s) of any commercial product(s)/device(s) and/or provider(s) of commercial services included in this educational activity. The intent of this disclosure is not to prevent a faculty member with a relevant financial or other relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. The France Foundation has identified and resolved any and all faculty conflicts of interest prior to the release of this activity.

Steering Committee and Work Group Disclosure

Harold R. Collard, MD, FCCP, has served as a consultant for Actelion, Amira, CV Therapeutics, Genzyme, Gilead, InterMune, Nektar, and Roche.

Kevin R. Flaherty, MD, MS, has received grant/research support from InterMune and NIH. He has served as a consultant for Boehringer Ingelheim, Fibrogen, Gilead, and GlaxoSmithKine. Dr. Flaherty has received honoraria from Boehringer Ingelheim, GlaxoSmithKline, Ortho-McNeil, Pfizer, and Sepracor.

Jeffery A. Golden, MD, has received research support from Actelion, Alnylam Pharmaceuticals, APT Pharmaceuticals, InterMune, and Johnson & Johnson.

Kevin O. Leslie, MD, has served as a consultant for Gilead and SuperDimension, Inc.

Steven D. Nathan, MD, has served as a consultant for and received honoraria from Actelion, Gilead, and United Therapeutics. He has received grant and research support from Actelion, Gilead, InterMune, and United Therapeutics.

Paul W. Noble, MD, FCCP, has served as a consultant for Actelion, Boehringer Ingelheim, Gilead, Human Genome Sciences, InterMune, Johnson & Johnson, Novartis, and Stromedix. He has served as a speaker for InterMune.

Imre Noth, MD, has received grants/research support from Actelion, Asthmatx, Centocor, Gilead, GlaxoSmithKline, and InterMune. He has served as a consultant for GlaxoSmithKline and Sepracor.

Maria L. Padilla, MD, has nothing to disclose.

Glenn D. Rosen, MD, has served as a consultant for Celgene and received honoraria from Boehringer Ingelheim, GlaxoSmithKline, Pfizer, and Schering-Plough.

Steven A. Sahn, MD, has received grant and research support from Centocor, Gilead, and InterMune. He has served as a consultant for InterMune, LAM Foundation, and Merck, and has received honoraria from Boehringer Ingelheim. He has received other financial or material support from UpToDate and PCCU.

Charlie Strange, MD, has received grants/research support from Actelion, Aeris, Inc, Emphasys Medical, Gilead, InterMune, National Institute of Health, and Talecris Biotherapeutics. He has served as consultant for AstraZeneca, Gilead, and Talecris Biotherapeutics. Dr. Strange has received honoraria from Actelion, AstraZeneca, Baxter, Gilead, GlaxoSmithKline, and Talecris Biotherapeutics.

W. Richard Webb, MD, has served as a consultant for Gilead and InterMune.

The France Foundation Staff: The staff involved with this activity have reported no relevant financial relationships with commercial interests.